Remove Bacteria Remove Clinical Development Remove Drug Delivery Systems
article thumbnail

Decoy-20 by Indaptus Therapeutics for Hepatocellular Carcinoma: Likelihood of Approval

Pharmaceutical Technology

Decoy-20 is under clinical development by Indaptus Therapeutics and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase I drugs for Hepatocellular Carcinoma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.